Compare NTLA & USA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | USA |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2016 | 1994 |
| Metric | NTLA | USA |
|---|---|---|
| Price | $12.72 | $5.98 |
| Analyst Decision | Buy | |
| Analyst Count | 23 | 0 |
| Target Price | ★ $20.02 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 1.1M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $62.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $5.40 |
| 52 Week High | $28.24 | $6.56 |
| Indicator | NTLA | USA |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 57.16 |
| Support Level | $12.55 | $5.65 |
| Resistance Level | $13.88 | $6.11 |
| Average True Range (ATR) | 0.66 | 0.05 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 53.28 | 59.37 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Liberty All Star Equity Fund is a diversified, closed-end management investment company. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.